Skip to content
2000
image of Bilateral Periorbital Erythema and Swelling as an Initial Presentation of Systemic Lupus Erythematosus: A Rare Case

Abstract

Introduction

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by multisystem involvement due to autoantibody production and immune complex deposition. While classical cutaneous manifestations, such as malar rash, are common, atypical presentations, like periorbital erythema and swelling, are rare and pose diagnostic challenges. Early recognition is crucial to prevent disease progression and complications.

Case Presentation

A 16-year-old girl presented with a three-month history of intermittent bilateral periorbital swelling. Clinical examination revealed pallor and localized alopecia with no significant systemic abnormalities. Laboratory investigations showed pancytopenia with normal renal, hepatic, and thyroid functions and unremarkable urinalysis, chest X-ray, and ECG. Autoimmune markers were positive, with a strongly positive ANA titer of 1:1000 and significantly elevated anti-dsDNA antibodies of 380 IU/mL (reference range: 0-200 IU/mL). According to the 2019 EULAR/ACR classification criteria, a diagnosis of SLE was established. The patient was treated with pulse intravenous methylprednisolone (1g daily for three days), followed by oral prednisolone (1 mg/kg/day), in a tapering regimen and hydroxychloroquine at standard doses. She showed marked improvement, with resolution of periorbital swelling, recovery of pancytopenia, and hair regrowth. At two-month follow-up, she remained asymptomatic and continued hydroxychloroquine for maintenance therapy.

Conclusion

This case underscores the importance of considering SLE in patients with atypical presentations, like periorbital erythema and pancytopenia. Early diagnosis based on clinical and serological findings, followed by appropriate therapy, can achieve remission and prevent complications. The case highlights the need for heightened clinical suspicion and multidisciplinary management in young patients.

Loading

Article metrics loading...

/content/journals/crr/10.2174/0115733971381153250418075039
2025-04-25
2025-09-05
Loading full text...

Full text loading...

References

  1. Tsokos G.C. Systemic lupus erythematosus. N. Engl. J. Med. 2011 365 22 2110 2121 10.1056/NEJMra1100359 22129255
    [Google Scholar]
  2. Kuhn A. Ruland V. Cutaneous lupus erythematosus: Insights into pathogenesis and therapeutic strategies. J. Autoimmun. 2020 110 102356
    [Google Scholar]
  3. Wu M.Y. Wang C.H. Ng C.Y. Kuo T.T. Chang Y.C. Yang C.H. Lin J.Y. Ho H.C. Chung W.H. Chen C.B. Periorbital erythema and swelling as a presenting sign of lupus erythematosus in tertiary referral centers and literature review. Lupus 2018 27 11 1828 1837 10.1177/0961203318792358 30134759
    [Google Scholar]
  4. Kasem Ali Sliman R. Saied H.M. Periorbital Edema as the Initial Manifestation of Pediatric Systemic Lupus Erythematosus. Clin. Med. Insights Case Rep. 2022 15 11795476221135430 10.1177/11795476221135430 36339327
    [Google Scholar]
  5. Malaviya A.N. Singh R.R. Kumar A. De A. Kumar A. Aradhye S. Systemic lupus erythematosus in northern India: A review of 329 cases. J. Assoc. Physicians India 1988 36 8 476 480, 484 3246502
    [Google Scholar]
  6. Albrecht J. Berlin J.A. Braverman I.M. Dermatology and rheumatology: The spectrum of cutaneous lupus erythematosus. J. Am. Acad. Dermatol. 1998 38 6 839 860
    [Google Scholar]
  7. Akbarian M. Khalkhali H.R. Bavarian R. Neuropsychiatric manifestations of lupus: A review. Lupus 2021 30 7 1050 1062 34152246
    [Google Scholar]
  8. Zahr Z.A. Baer A.N. Hematologic manifestations of systemic lupus erythematosus. Hematol. Oncol. Clin. North Am. 2010 24 1 165 186
    [Google Scholar]
  9. Aringer M. Costenbader K. Daikh D. Brinks R. Mosca M. Ramsey-Goldman R. Smolen J.S. Wofsy D. Boumpas D.T. Kamen D.L. Jayne D. Cervera R. Costedoat-Chalumeau N. Diamond B. Gladman D.D. Hahn B. Hiepe F. Jacobsen S. Khanna D. Lerstrøm K. Massarotti E. McCune J. Ruiz-Irastorza G. Sanchez-Guerrero J. Schneider M. Urowitz M. Bertsias G. Hoyer B.F. Leuchten N. Tani C. Tedeschi S.K. Touma Z. Schmajuk G. Anic B. Assan F. Chan T.M. Clarke A.E. Crow M.K. Czirják L. Doria A. Graninger W. Halda-Kiss B. Hasni S. Izmirly P.M. Jung M. Kumánovics G. Mariette X. Padjen I. Pego-Reigosa J.M. Romero-Diaz J. Rúa-Figueroa Fernández Í. Seror R. Stummvoll G.H. Tanaka Y. Tektonidou M.G. Vasconcelos C. Vital E.M. Wallace D.J. Yavuz S. Meroni P.L. Fritzler M.J. Naden R. Dörner T. Johnson S.R. 2019 European league against rheumatism/american college of rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheumatol. 2019 71 9 1400 1412 10.1002/art.40930 31385462
    [Google Scholar]
  10. Vaidya S. Bichile L.S. Systemic lupus erythematosus: Clinical and laboratory profile in Indian patients. J. Postgrad. Med. 2003 49 2 92 95
    [Google Scholar]
  11. Singh J. Dinkar A. Gupta P. Uncommon manifestations in tuberculosis: An expanding clinical spectrum from North India. Int. J. Mycobacteriol. 2022 11 1 30 37 10.4103/ijmy.ijmy_242_21 35295021
    [Google Scholar]
  12. Singh J. Dinkar A. Gupta P. Atam V. Vitamin B12 deficiency in northern India tertiary care: Prevalence, risk factors and clinical characteristics. J. Family Med. Prim. Care 2022 11 6 2381 2388 10.4103/jfmpc.jfmpc_650_21 36119310
    [Google Scholar]
  13. Alam F. Singh J. Kumar N. Kumar K. Dinkar A. Massive splenomegaly with pancytopenia in an adult: Gaucher’s disease. Cardiovasc. Hematol. Disord. Drug Targets 2023 23 2 136 140 10.2174/011871529X253966230922110202 37877562
    [Google Scholar]
  14. Makeeva V. Seminario-Vidal L. Beckum K. Sami N. Bilateral periorbital swelling as the initial presentation of cutaneous lupus erythematosus. JAAD Case Rep. 2016 2 1 72 76 10.1016/j.jdcr.2015.12.009 27051834
    [Google Scholar]
  15. Ruiz-Irastorza G. Ramos-Casals M. Brito-Zerón P. Khamashta M.A. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: A systematic review. Ann. Rheum. Dis. 2010 69 1 20 28 10.1136/ard.2008.101766 19103632
    [Google Scholar]
  16. Fanouriakis A. Kostopoulou M. Alunno A. Aringer M. Bajema I. Boletis J.N. Cervera R. Doria A. Gordon C. Govoni M. Houssiau F. Jayne D. Kouloumas M. Kuhn A. Larsen J.L. Lerstrøm K. Moroni G. Mosca M. Schneider M. Smolen J.S. Svenungsson E. Tesar V. Tincani A. Troldborg A. Vollenhoven V.R. Wenzel J. Bertsias G. Boumpas D.T. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann. Rheum. Dis. 2019 78 6 736 745 10.1136/annrheumdis‑2019‑215089 30926722
    [Google Scholar]
  17. Navarra S.V. Guzmán R.M. Gallacher A.E. Hall S. Levy R.A. Jimenez R.E. Li E.K.M. Thomas M. Kim H.Y. León M.G. Tanasescu C. Nasonov E. Lan J.L. Pineda L. Zhong Z.J. Freimuth W. Petri M.A. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-controlled, phase 3 trial. Lancet 2011 377 9767 721 731 10.1016/S0140‑6736(10)61354‑2 21296403
    [Google Scholar]
  18. Morand E.F. Furie R. Tanaka Y. Bruce I.N. Askanase A.D. Richez C. Bae S.C. Brohawn P.Z. Pineda L. Berglind A. Tummala R. Trial of anifrolumab in active systemic lupus erythematosus. N. Engl. J. Med. 2020 382 3 211 221 10.1056/NEJMoa1912196 31851795
    [Google Scholar]
/content/journals/crr/10.2174/0115733971381153250418075039
Loading
/content/journals/crr/10.2174/0115733971381153250418075039
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test